New hope for tough lymphoma: immunotherapy plus chemo
NCT ID NCT06249191
First seen Apr 28, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This study tests whether adding the immunotherapy drug mosunetuzumab to standard chemotherapy is safe and works better for people with a fast-growing type of lymphoma that has a specific genetic change (c-Myc rearrangement). About 30 adults aged 18-75 who have not been treated before will receive the combination. The goal is to see if the combo can shrink or eliminate the cancer more effectively than chemo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.